# The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

> **NCT02581202** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 216 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** lopinavir/ritonavir
- **DRUG:** lamivudine

## Key facts

- **NCT ID:** NCT02581202
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2017-05-27
- **Final completion:** 2017-05-27
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581202, "The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02581202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*